CAR-T therapy frees three rheumatoid arthritis patients from drugs

Charite Universitaetsmedizin Berlin, working with the German Rheumatology Research Centre, reported on 27 August 2026 in Nature Medicine that six people with rheumatoid arthritis had been treated with CAR T cells directed at CD19. The participants, three women and three men aged 31 to 69, had exhausted up to eight targeted or biologic therapies over roughly a decade.

Rheumatoid arthritis is normally managed by suppressing inflammation indefinitely. This approach instead removes the cells producing it. The engineered T cells hunt CD19-positive B cells, including the memory B cells that persist in joints, bone marrow and lymph nodes and that conventional antibody drugs reach poorly. Disease activity fell markedly in all six patients. Three sustained remission with no rheumatoid arthritis medication at all through follow-up of up to twelve months, and autoantibody levels dropped sharply, with pathological B cells no longer detectable in almost all participants.

Every participant developed cytokine release syndrome, in each case mild to moderate. The investigators recorded no severe neurological complications and no serious adverse events, with infections rare. Prof. David Simon of the hospital’s rheumatology and clinical immunology department designed the trial for this group. Six patients is a first-in-disease cohort, not evidence of durability, and the therapy remains a hospital procedure requiring cell manufacture rather than a prescription.